Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 15/20 | 0.68 |
| ▸ | ACE2 | Q9BYF1 | 13/20 | 0.68 |
| ▸ | ACE | P12821 | 13/20 | 0.68 |
| ▸ | CPA1 | P15085 | 11/20 | 0.68 |
| ▸ | ACACB | O00763 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CTSS | P25774 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6436289 | 1.00 | MME (0.68) | MMEACE2ACECPA1ACACB | |
| SCHEMBL6857632 | 1.00 | MME (0.68) | MMEACE2ACECPA1ACACB | |
| Afalanine SCHEMBL331330 | 0.91 | CTSS (0.65) | MMEACE2ACECPA1LMNA | |
| Afalanine SCHEMBL158612 | 0.91 | CTSS (0.65) | MMEACE2ACECPA1LMNA | |
| Afalanine SCHEMBL8587729 | 0.91 | CTSS (0.65) | MMEACE2ACECPA1LMNA | |
| Afalanine SCHEMBL158613 | 0.91 | CTSS (0.65) | MMEACE2ACECPA1LMNA | |
| SCHEMBL23512376 | 0.90 | MME (0.61) | MMEACE2ACECPA1ACACB | |
| Afalanine SCHEMBL8054567 | 0.90 | CTSS (0.63) | MMEACE2ACECPA1LMNA | |
| Afalanine SCHEMBL5493802 | 0.90 | CTSS (0.68) | MMEACE2ACECPA1LMNA | |
| Afalanine SCHEMBL8054139 | 0.90 | CTSS (0.63) | MMEACE2ACECPA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072246-A9 | COMPOUNDS AND METHODS FOR SKIPPING EXON 50 IN DUCHENNE MUSCULAR DYSTROPHY | ENTRADA THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025072246-A1 | COMPOUNDS AND METHODS FOR SKIPPING EXON 50 IN DUCHENNE MUSCULAR DYSTROPHY | ENTRADA THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-9181175-B2 | Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid | Zhejiang Jiuzhous Pharmaceutical Co., Ltd. (CN) | 2015-11-10 | — | — | US | disclosed |
| US-9181175-B2 | Process for manufacture and resolution of 2-acylamino-3-diphenylpropanoic acid | Zhejiang Jiuzhous Pharmaceutical Co., Ltd. (CN) | 2015-11-10 | — | — | US | disclosed |
| EP-2387558-B1 | PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID | ZHEJIANG JIUZHOU PHARM CO LTD (CN) | 2014-08-27 | — | — | EP | disclosed |
| US-20140179947-A1 | PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2014-06-26 | — | — | US | disclosed |
| US-20140179947-A1 | PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2014-06-26 | — | — | US | disclosed |
| US-20120016151-A1 | PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
| US-20120016151-A1 | PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID | NOVARTIS AG (CH) | 2012-01-19 | — | — | US | disclosed |
| WO-2010081410-A1 | PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2010-07-22 | — | — | WO | disclosed |
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179947-A1 | PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID | DNPEP, MME, DPP7 | MME 2/4885ACE2 79/4885ACE 29/4885 |
| US-20120016151-A1 | PROCESS FOR MANUFACTURE AND RESOLUTION OF 2-ACYLAMINO-3-DIPHENYLPROPANOIC ACID | DNPEP, MME, DPP7 | MME 2/4885ACE2 79/4885ACE 29/4885 |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | MME 1731/4885ACE2 370/4885ACE 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.